Nektar Therapeutics (NASDAQ:NKTR) had its price objective upped by Mizuho from $45.00 to $89.00 in a research note issued on Monday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Mizuho’s price target suggests a potential upside of 24.32% from the company’s previous close.
NKTR has been the subject of several other research reports. Roth Capital set a $45.00 target price on shares of Nektar Therapeutics and gave the company a “buy” rating in a report on Monday, November 13th. Canaccord Genuity Group raised their price objective on shares of Nektar Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a report on Wednesday, November 15th. Jefferies Group raised their price objective on shares of Nektar Therapeutics from $2.12 to $88.00 and gave the stock a “buy” rating in a report on Tuesday, January 16th. Cowen began coverage on shares of Nektar Therapeutics in a report on Tuesday, November 7th. They set an “outperform” rating for the company. Finally, JPMorgan Chase & Co. restated a “buy” rating and set a $44.00 price objective on shares of Nektar Therapeutics in a report on Monday, November 13th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $46.17.
Shares of Nektar Therapeutics (NKTR) opened at $71.59 on Monday. The company has a market cap of $11,273.11, a PE ratio of -99.43 and a beta of 1.81. The company has a quick ratio of 3.99, a current ratio of 4.14 and a debt-to-equity ratio of 2.91. Nektar Therapeutics has a 1-year low of $11.41 and a 1-year high of $75.33.
Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.21 by $0.16. The company had revenue of $152.90 million during the quarter, compared to the consensus estimate of $126.50 million. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. The firm’s revenue for the quarter was up 321.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.32) earnings per share. sell-side analysts expect that Nektar Therapeutics will post -0.76 EPS for the current year.
In other news, SVP Maninder Hora sold 5,117 shares of Nektar Therapeutics stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $25.07, for a total value of $128,283.19. Following the completion of the transaction, the senior vice president now owns 52,016 shares in the company, valued at $1,304,041.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christopher A. Kuebler sold 30,000 shares of Nektar Therapeutics stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $58.66, for a total transaction of $1,759,800.00. Following the completion of the transaction, the director now owns 70,500 shares of the company’s stock, valued at approximately $4,135,530. The disclosure for this sale can be found here. Insiders sold 614,017 shares of company stock valued at $20,587,527 in the last quarter. Corporate insiders own 5.44% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of NKTR. Janus Henderson Group PLC purchased a new position in shares of Nektar Therapeutics in the second quarter worth about $34,661,000. PointState Capital LP increased its stake in shares of Nektar Therapeutics by 281.7% in the second quarter. PointState Capital LP now owns 1,731,000 shares of the biopharmaceutical company’s stock worth $33,841,000 after purchasing an additional 1,277,500 shares in the last quarter. Rubric Capital Management LP purchased a new position in shares of Nektar Therapeutics in the third quarter worth about $23,924,000. State Street Corp increased its stake in shares of Nektar Therapeutics by 11.3% in the second quarter. State Street Corp now owns 4,408,270 shares of the biopharmaceutical company’s stock worth $86,179,000 after purchasing an additional 447,023 shares in the last quarter. Finally, Numeric Investors LLC increased its stake in shares of Nektar Therapeutics by 2,111.5% in the second quarter. Numeric Investors LLC now owns 440,729 shares of the biopharmaceutical company’s stock worth $8,616,000 after purchasing an additional 420,800 shares in the last quarter. Hedge funds and other institutional investors own 96.00% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Nektar Therapeutics (NKTR) Price Target Raised to $89.00” was originally reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.truebluetribune.com/2018/01/22/nektar-therapeutics-nktr-price-target-raised-to-89-00.html.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.